section name header

Evidence summaries

Mycophenolic Acid for Kidney Transplant Recipients

Antimetabolites (azathioprine, mycophenolate) may be effective for mortality and graft survival in kidney transplant recipients.Mycophenolate mofetil may be more effective than azathioprine for graft survival and prevention of acute rejection after kidney transplantation. However, cytomegalovirus disease may be more common with mycophenolate mofetil. Level of evidence: "C"

Comment: The quality of evidence is downgraded by study limitations (unclear allocation concealment, unclear blinding of outcome assessment, incomplete outcome data and mostly commercially funded studies).

Summary

A Cochrane review [Abstract] 1 included 23 studies with a total of 3 301 subjects comparing mycophenolate mofetil (MMF, a mycophenolic acid) with azathioprine (AZA). MMF treatment reduced the risk for graft loss including death and for death-censored graft loss, and the risk for any acute rejection, biopsy-proven acute rejection and antibody-treated acute rejection T1. No statistically significant difference for MMF versus AZA treatment was found for all-cause mortality. Pooled analyses failed to show a significant and meaningful difference between MMF and AZA in kidney function measures.Data on malignancies and infections were sparse, except for cytomegalovirus (CMV) infections. Adverse event profiles varied: gastrointestinal symptoms were more likely in MMF treated patients and thrombocytopenia and elevated liver enzymes were more common in AZA treatment.

Table 1. Mycophenolate mofetil (MMF) versus azathioprine (AZA) for primary immunosuppression in kidney transplant recipients

OutcomeRelative effect(95% CI)Assumed risk - control=AZACorresponding risk - intervention=MMFNumber of participants (studies)
Death, all causeFollow-up: 0.5 to 5 yearsRR 0.95 (0.7 to 1.29)49/100047/1000(34 to 63)2987 (16)
Graft loss, censored for deathFollow-up: 0.5 to 6 yearsRR 0.78 (0.61 to 0.98)11/1009/100(7 to 11)2540 (17)
Acute rejection, totalFollow-up: 0.5 to 5 yearsRR 0.65 (0.57 to 0.73)35/10023/100(20 to 26)3301 (22)
Infection, CMV tissue invasive Follow-up: 0.5 to 3 yearsRR 1.7 (1.1 to 2.61)4/1007/100(5 to 11)1510 (7)

Another Cochrane review [Abstract] 2 included 70 studies with a total of 17 462 subjects. No differences in the hard-end points of patient and graft survival were demonstrated for or against TOR inhibitor (TORi; sirolimus and everolimus) in comparison with calcineurin inhibitors (CNI; ciclosporin or tacrolimus) and antimetabolites (azathioprine, mycophenolate) (table T2). Need to change treatment and wound complications were higher with TOR-i, but there were less cytomegalovirus (CMV) infections (table T2).

TOR-i versus antimetabolites: outcomes up to 2 years (main outcomes) for primary immunosuppression

Outcomes (up to 2 years for primary outcomes)Relative effect(95% CI)Risk with antimetabolitesRisk with TOR-I (95% CI)No. of participants(studies)Certainty of the evidence
Death (all causes)RR 1.06 (0.84 to 1.33)29 per 100031 per 1000(24 to 38)10 482 (31) Moderate
Graft loss censored for deathRR 1.09(0.82 to 1.45)35 per 100038 per 1000(29 to 51)8 966 (26) Moderate
CMV infectionRR 0.44(0.34 to 0.58)136 per 100059 per 1000(46 to 78)10 049 (26) Moderate
Adverse wound outcomes: all complicationsRR 1.56(1.28 to 1.90)155 per 1000241 per 1000 (199 to 297)6 913 (17) Moderate
Number needing to change treatmentRR 1.56 (1.28 to 1.90)174 per 1000248 per 1000(203 to 302)9747 (25) Moderate

Clinical comments

Note

Date of latest search: 2020-01-10

    References

    • Wagner M, Earley AK, Webster AC et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2015;(12):CD007746. [PubMed]
    • Hahn D, Hodson EM, Hamiwka LA et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2019;12():CD004290.[PubMed]

Primary/Secondary Keywords